Skip to main content
JEONJINBIO CO., LTD. logo

JEONJINBIO CO., LTD. — Investor Relations & Filings

Ticker · 110020 ISIN · KR7110020005 KO Manufacturing
Open in API
Filings indexed 371 across all filing types
Latest filing 2022-03-07 AGM Information
Country KR South Korea
Listing KO 110020

About JEONJINBIO CO., LTD.

http://jjbious.com/01

JEONJINBIO CO., LTD. is a biotechnology company specializing in the research, development, and production of products for pest control and the mitigation of damage from nuisance animals. The company's core offerings consist of natural bio-pesticides and repellents formulated from natural materials as alternatives to conventional chemical products. Its product line includes specialized solutions for repelling birds, boars, and other animals. The company emphasizes innovation and safety, supported by its dedicated research and development center and various product certifications, including USA EPA approval for its bird repellent.

Recent filings

Filing Released Lang Actions
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Jeonjin BioPharm. It outlines the date, location, and agenda items for the upcoming Annual General Meeting, including the approval of financial statements, director appointments, and changes to business objectives. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and request their participation/votes. Therefore, it is classified as a Proxy Solicitation & Information Statement (PSI).
2022-03-07 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Annual General Meeting' (주주총회소집공고) for Jeonjin BioPharm. It contains the agenda for the meeting, including the approval of financial statements, director appointments, and remuneration limits. It also includes detailed financial statements (balance sheet, income statement, etc.) as part of the 'Management Reference' (경영참고사항) required for shareholders to review before the meeting. This is a standard proxy solicitation document provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon.
2022-03-07 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It contains the meeting agenda, information about the solicitors, and the company's financial statements (balance sheet, income statement, etc.) as required by law to inform shareholders before they cast their votes. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2022-03-07 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition of shares and convertible bonds by a major shareholder (Mirto Co., Ltd. and YOO ANDY C) in the company 'Jeonjin BioPharm'. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2022-02-07 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Jeonjin BioPharm) announcing a significant change (over 15%) in revenue or profit structure. This is a standard regulatory disclosure requirement in the Korean market (DART system) for material financial changes. It provides specific financial data (revenue, operating profit, net income) and reasons for the change. It is not a full annual report, but a specific financial disclosure announcement, which falls under the 'Regulatory Filings' category as it is a mandatory disclosure of material information. FY 2021
2022-02-07 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as the 5% rule filing). It details the change in share ownership by Fine Value Asset Management in Jeonjin BioPharm. This type of filing is a mandatory disclosure to the Financial Services Commission and the Korea Exchange regarding significant changes in shareholding, which falls under the 'Major Shareholding Notification' category.
2022-02-04 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.